In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

GLP-1 supplements are advertised as a cheaper alternative to weight loss with Ozempic or Wegovy. Doctors explain if they help ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...